CONSORT diagram

Randomized
n = 141

Allocated to intervention *n =78*

Allocated to **control condition** *n =63*

Followed *n = 78*
Lost to follow-up *n = 0*

Followed *n = 63*
Lost to follow-up *n = 0*

With primary outcome *n = 75*
Analysed *n =71*
Excluded from analysis *n =7*
    Reasons:
4 not sufficient baseline data
1 not sufficient intervention data
2 not sufficient both periods

With primary outcome *n = 56*
Analysed *n =52*
Excluded from analysis *n =8*
    Reasons:
4 not sufficient baseline data
3 not sufficient intervention data
1 not sufficient both periods

Followed *n=74*
Lost to 6m follow-up *n = 4*
Reasons:
1 dead (during intervention period)
3 discharged from services

Followed *n=58*
Lost to 6m follow-up *n = 5*
Reasons:
1 withdrawn (baseline)
2 withdrew (baseline)
1 moved abroad (during 6m follow-up)
1 not in community

With primary outcome *n = 61*
Analysed *n =58*
Excluded from analysis *n =16*
    Reasons:
5 no depot data in one or both
   periods
3 not sufficient baseline data
6 not sufficient follow-up data
2 not sufficient both periods

With primary outcome *n = 45*
Analysed *n =41*
Excluded from analysis *n =17*
    Reasons:
5 no depot data in one or both
   periods
1 not sufficient baseline data
9 not sufficient follow-up data
2 not sufficient both periods
1 oral medication only

Followed *n = 75*
Lost to follow-up *n = 1*
Reasons:
1 discharged to GP

Followed *n = 55*
Lost to follow-up *n = 4*
    Reasons:
2 discharged to GP
1 died
1 not in community

Analysis

With primary outcome *n = 66*
Analysed *n =66*
Excluded from analysis *n =9*
   Reasons:
3 no depot data
3 not sufficient depot data
3 oral medication only

With primary outcome *n = 50*
Analysed *n =49*
Excluded from analysis *n =6*
   Reasons:
1 no depot data
2 not sufficient depot data
3 oral medication only

Figure 1 Consort diagram illustrating participant flow across the different stages of the trial

Table 1 Socio-demographic and clinical characteristics at baseline, end of intervention, and 6- and 24-month follow-ups.

	Baseline				End of Intervention				6-month follow-up				24-month follow-up			
	Incentives (N=78)		Control (N = 63)		Incentives (N = 77)		Control (N = 60)		Incentives (N =76)		Control (N = 60)		Incentives (N = 77)		Control (N = 59)	
	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %	mean or n	SD or %
Demographics																
Age (years)	44.4	9.6	42.7	10.2	45.2	9.3	43.3	10.0	45.6	9.3	43.7	10.0	47.2	9.3	45.5	9.9
Male sex	59	76%	46	73%	59	76%	45	76%	58	76%	46	77%	59	77%	45	76%
Ethnicity																
White	49	63%	34	57%	49	63%	33	56%	47	62%	34	57%	48	62%	33	56%
Black	17	22%	14	23%	17	22%	14	24%	17	22%	14	23%	17	22%	14	24%
Asian	5	6%	4	7%	5	6%	4	7%	5	7%	4	7%	5	6%	4	7%
Mixed and other	7	9%	8	13%	7	9%	8	14%	7	9%	8	13%	7	9%	8	14%
Living situation																
Married/co-habiting	8	10%	10	16%	8	10%	7	12%	6	8%	8	13%	12	16%	9	15%
Independent accommodation	53	68%	49	83%	53	68%	50	85%	52	68%	47	81%	48	64%	45	80%
Living alone	41	62%	34	62%	43	55%	35	59%	40	63%	34	64%	44	60%	33	69%
Paid employment (any)	3	4%	1	2%	4	5%	0	0%	4	5%	2	3%	4	5%	1	2%
Receiving benefits	76	99%	58	100%	70	97%	54	98%	70	97%	57	97%	68	96%	48	100%
Diagnosis																
Schizophrenia	61	78%	52	82%	56	81%	45	83%	57	75%	45	75%	56	73%	45	76%
Schizo-affective disorders	9	12%	8	12%	8	12%	5	9%	11	14%	11	18%	11	14%	7	12%
Bipolar affective disorder	6	8%	1	2%	4	6%	3	6%	5	7%	3	5%	5	7%	4	7%
Other psychosis	2	2%	1	2%	1	1%	0	0%	2	3%	0	0%	1	1%	0	0%
Other diagnosis	0	0%	1	2%	0	0%	1	2%	1	1%	1	2%	3	1%	3	5%
Clinical history																
Duration of illness (years)	18.2	8.6	17.3	8.5	19.2	8.6	18.3	8.6	19.9	8.6	18.8	8.5	21.2	8.6	20.5	8.5
Number of psychiatric hospitalisations over assessment period	0.9	2.7	59	0.6	0.7	1.4	0.6	1.4	0.3	0.7	0.2	0.6	0.9	2.3	0.5	1.2

Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods.

Depot cycle	Baseline				End of Intervention				1-6m Follow-up				7-24m Follow-up			
	Incentives		Control		Incentives		Control		Incentives		Control		Incentives		Control	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
1/52	4	5.6	3	5.5	2	2.7	1	1.8	2	3.3	3	6.7	3	4	1	2
2/52	50	69.4	34	61.8	51	68.0	29	51.8	38	62.3	20	32.8	44	63	24	44
3/52	5	6.9	2	3.6	4	5.3	3	5.4	4	6.6	2	4.5	3	7	1	2
4/52	12	16.7	13	23.6	13	17.3	18	32.1	11	18.0	13	28.9	11	16	20	37
Variable	1	1.4	3	5.5	5	6.7	5	8.9	6	9.8	7	15.6	7	10	8	15
Total	72	100	55	100	75	100	56	100	61	100	45	100	70	100	54	100

Table 3 Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.

Treatment cycle	Baseline period (N=123)				Intervention period (N=123)				1-6-month follow-up (N=110)				7-24-month follow-up (N=110)			
	Incentives N=71		Control, (N=52)		Incentives (N=71)		Control, (N=52)		Incentives (N=66)		Control (N=54)		Incentives (N=66)		Control (N=54)	
	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence
1/52	2	54%	1	45%	2	82%	1	49%	3	76%	3	64%	3	78%	1	85%
2/52	49	67%	27	68%	49	83%	27	74%	41	71%	23	74%	41	67%	24	73%
3/52	4	76%	3	66%	4	97%	3	44%	4	77%	2	83%	5	74%	1	77%
4/52	12	76%	16	66%	12	92%	16	73%	13	71%	20	74%	11	66%	18	73%
5/52	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1	71%	0	n/a	n/a	n/a	n/a	n/a
Variable cycle	4	60%	5	62%	4	72%	5	72%	4	59%	6	87%	6	68%	6	75%

Note:n/a = not applicable

Table 4 Primary and secondary outcomes at baseline, end of intervention, and 6- and 24-months follow-ups.

	Period	Incentives n* 74[†]/75[¥]	Number (%) or Means (SD)		Control n* 58[†]/56[¥]	Number (%) or Means (SD)		Type of effect estimate	Adjusted effect estimate (intervention vs. control)	P-value	ICC[∫]
Primary outcome											
Adherence (percentage) to depot medication	Baseline	72	69%	(16%)	55	67%	(16%)				
	12-month intervention	75	85%	(15%)	56	71%	(22%)	Difference in means[‡]	11.5% (3.9% to 19.0%)[§]	0.0003	0.28
	1-6-month follow-up	58	70%	(24%)	41	77%	(19%)	Difference in means[‡]	-7.4% (-17.0% to 2.1%)	0.127	0.175
	7-24-month follow-up	66	68%	(21%)	50	74%	(19%)	Difference in means	-5.7% (-13.1% to 1.7%)	0.130	n/a
Secondary outcomes											
Achieving at least 95% adherence versus not	Baseline	72	5	(7%)	55	1	(2%)				
	12-month intervention	75	21	(28%)	56	3	(5%)	Odds ratio[‡]	8.21 (2.00 to 33.67)	0.003	0.04
	1-6-month follow-up	66	5	(8%)	54	9	(17%)	Odds ratio[‡]	0.42 (0.11 to 1.61)	0.205	<0.001
	7-24-month follow-up	66	4	(6%)	50	5	(10%)	Odds ratio	0.42 (0.06 to 3.02)	0.392	0.42
At least one psychiatric hospital admission	Baseline	78	14	(19%)	60	10	(17%)				
	12-month intervention	78	15	(19%)	59	14	(24%)				
	1-6-month follow-up	74	15	(20%)	58	8	(14%)				
	7-24-month follow-up	77	24	(31%)	60	10	(17%)				
At least one suicide attempt versus none	Baseline	78	9	(12%)	59	7	(12%)				
	12-month intervention	77	8	(10%)	58	4	(7%)				
	1-6-month follow-up	73	3	(4%)	58	3	(5%)				
	7-24-month follow-up	75	5	(7%)	58	3	(5%)				
At least one violent incident versus none	Baseline	77	15	(20%)	60	10	(17%)				
	12-month intervention	77	10	(13%)	58	7	(12%)				

		n			n		
	1-6-month follow-up	73	4	(6%)	58	3	(5%)
	7-24-month follow-up	75	11	(15%)	58	7	(12%)
At least one police arrest versus none	Baseline	77	13	(18%)	60	9	(16%)
	12-month intervention	77	10	(13%)	60	10	(17%)
	1-6-month follow-up	73	6	(8%)	58	3	(5%)
	7-24-month follow-up	75	14	(19%)	58	10	(17%)

*n is the number of patients in either group with both a baseline and follow up period for the specified outcome

† Number of patients during 6-month follow-up: Excludes 9 patients on whom no data were collected during the 6 month follow up period: 2 who withdrew immediately after randomisation and 1 who was withdrawn as was not being prescribed depot medication, 1 who died during the intervention period, 2 who were discharged during the intervention period, 1 who was discharged during the 6 follow-up period, 1 who moved abroad during follow up and 1 who was out of the community for all of the follow up period.

¥ Number of patients during 24-month follow-up. Excludes 4 patients who were lost to follow-up before the start of the 6 months follow-up period. Of the remaining 137 patients, 5 were lost during the 6 month follow up and a further 5 were lost to follow-up during the final phase of the study. Four patients lost during the 6-month follow up returned to the study.

‡Each model was adjusted for baseline measure of outcome, MINI score category (low vs. high) and average treatment cycle during baseline, and includes a random effect for team.

Table 5 Sensitivity analysis of primary outcome at the two follow-up periods

Analysis population	1-6-month follow-up				7-24-month follow-up			
	N	Difference in mean adherence	95% confidence interval	p-value	N	Difference in mean adherence	95% confidence interval	p-value
Main analysis: all participants with ≥ 4 months' depot data	108	-6.2%	-13.1% to 0.7%	0.078	116	-5.7%*	-13.1% to 1.7%	0.130
All participants as above, setting adherence to 100% for those discharged to GP	130	-5.0%	-14.7 % to 4.7%	0.316	119	-6.2%*	-13.6% to 1.1%	0.097
All participants as above but setting adherence to 0% for refusers	112	-4.9%	-14.3% to 4.2%	0.312	124	-6.4%**	-15.0% - 2.1%	0.142

Note: * Simple linear regression model including only a fixed effect for intervention versus control. Clustering by team ignorable as the ICC was -0.05; ** Linear mixed effects model including only a fixed effect for intervention versus control. The model-based ICC was <0.001.

Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods.

Depot cycle	Baseline				End of Intervention				1-6m Follow-up				7-24m Follow-up			
	Incentives		Control		Incentives		Control		Incentives		Control		Incentives		Control	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
1/52	4	5.6	3	5.5	2	2.7	1	1.8	2	3.3	3	6.7	3	4	1	2
2/52	50	69.4	34	61.8	51	68.0	29	51.8	38	62.3	20	32.8	44	63	24	44
3/52	5	6.9	2	3.6	4	5.3	3	5.4	4	6.6	2	4.5	3	7	1	2
4/52	12	16.7	13	23.6	13	17.3	18	32.1	11	18.0	13	28.9	11	16	20	37
Variable	1	1.4	3	5.5	5	6.7	5	8.9	6	9.8	7	15.6	7	10	8	15
Total	72	100	55	100	75	100	56	100	61	100	45	100	70	100	54	100

Table 3 Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.

Treatment cycle	Baseline period (N=123)				Intervention period (N=123)				1-6-month follow-up (N=110)				7-24-month follow-up (N=110)			
	Incentives N=71		Control, (N=52)		Incentives (N=71)		Control, (N=52)		Incentives (N=66)		Control (N=54)		Incentives (N=66)		Control (N=54)	
	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence	N	Mean adherence
1/52	2	54%	1	45%	2	82%	1	49%	3	76%	3	64%	3	78%	1	85%
2/52	49	67%	27	68%	49	83%	27	74%	41	71%	23	74%	41	67%	24	73%
3/52	4	76%	3	66%	4	97%	3	44%	4	77%	2	83%	5	74%	1	77%
4/52	12	76%	16	66%	12	92%	16	73%	13	71%	20	74%	11	66%	18	73%
5/52	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1	71%	0	n/a	n/a	n/a	n/a	n/a
Variable cycle	4	60%	5	62%	4	72%	5	72%	4	59%	6	87%	6	68%	6	75%

Note:n/a = not applicable